Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials
CONCLUSION: Most studies suggested that upadacitinib has no statistically significant difference in the studied safety outcomes compared to active treatments or placebo in patients with RA, PsA, AS, AD, UC, and CD. A few studies reported higher rates, but findings were inconsistent with limited interpretation.PMID:38169057 | DOI:10.1007/s12325-023-02732-6 (Source: Adv Data)
Source: Adv Data - January 3, 2024 Category: Epidemiology Authors: Eduardo Mysler Gerd R Burmester Christopher D Saffore John Liu Lani Wegrzyn Chelsey Yang Keith A Betts Yan Wang Alan D Irvine Remo Panaccione Source Type: research
Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials
CONCLUSION: Most studies suggested that upadacitinib has no statistically significant difference in the studied safety outcomes compared to active treatments or placebo in patients with RA, PsA, AS, AD, UC, and CD. A few studies reported higher rates, but findings were inconsistent with limited interpretation.PMID:38169057 | DOI:10.1007/s12325-023-02732-6 (Source: Adv Data)
Source: Adv Data - January 3, 2024 Category: Epidemiology Authors: Eduardo Mysler Gerd R Burmester Christopher D Saffore John Liu Lani Wegrzyn Chelsey Yang Keith A Betts Yan Wang Alan D Irvine Remo Panaccione Source Type: research
Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials
ConclusionMost studies suggested that upadacitinib has no statistically significant difference in the studied safety outcomes compared to active treatments or placebo in patients with RA, PsA, AS, AD, UC, and CD. A few studies reported higher rates, but findings were inconsistent with limited interpretation. (Source: Advances in Therapy)
Source: Advances in Therapy - January 2, 2024 Category: Drugs & Pharmacology Source Type: research
GSE232131 T-cell instructed monocyte activation is a key pathological feature in Ankylosing Spondylitis and provides novel therapeutic opportunities
Contributors : Feng Liu ; Jiaqi Li ; Claudia Worth ; Davide Simone ; Lihua Duan ; Paul Bowness ; Liye ChenSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensActivated T-cells potently stimulated monocytes from patients with AS to produce IL-1 β and IL-23. These in turn act back on T cells to enhance Th17 responses. T-cell activated monocytes are heterogeneous but include a subset of “super proinflammatory monocytes” not induced by LPS activation and for enriched for AS risk genes, including ERN1. Importantly, we identify a populati on of CD14+ myeloid cells highly enriched i...
Source: GEO: Gene Expression Omnibus - January 1, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
